CorrectSequence Therapeutics (Correctseq) is a clinical-stage biotechnology company dedicated to developing gene-editing therapies using our innovative base editing technology to help people with severe diseases. We have developed multiple base editing systems and our base editors offer significant advantages in controlling off-target effects and improving in vivo editing efficiency. Our base editing systems are compatible with various delivery approaches including ex vivo electroporation to HSC/T-cells, as well as in vivo delivery via LNP or AAV. Multiple pipelines for genetic diseases, cancer immunotherapy, metabolic diseases, and infectious diseases are under development. We have set up R&D and manufacturing centers in Shanghai, and regulatory and clinical operation center in Beijing. Our world-class R&D laboratory, CMC process development lab and cGMP manufacturing facility guarantee the rapid translation and application of our innovative research.